ff India Biz (27% of Sales): Weak sales (-16.3% YoY) in domestic business is attributable to one-time inventory reduction in supply chain and high YoY base, excluding which , SUNP could have reported a low single-digit decline. SUNP launched 13 new products in 2QFY19. ff R&D; Spend: SUNP's R&D; spend stood at 6.4% vs. 6.8% in 1QFY19). The Management expects R&D; spend to increase in 2HFY19E owing to specialty clinical development programme. SUNP is focussing on calibrating R&D; investments of generic portfolio (low value). ff SUNP provided Rs12.1bn towards Modafinil anti-trust litigation (Rs9.5bn in 1QFY18). As this is...